ATyr Pharma Completes Enrollment Of 268 Patients, Exceeding Target Enrollment In Global Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis
ATyr Pharma Completes Enrollment Of 268 Patients, Exceeding Target Enrollment In Global Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis
SAN DIEGO, July 22, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has completed enrollment in its global pivotal Phase 3 EFZO-FIT study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease with limited treatment options. The study enrolled 268 patients at 85 centers in 9 countries, exceeding target enrollment. Topline data from the study are expected in the third quarter of 2025.Study enrolled 268 patients, exceeding target enrollment.
该研究纳入268名患者，超过了目标招募人数。
Largest interventional study ever to be conducted in pulmonary sarcoidosis.
历史上最大的肺结节病干预研究。
Topline data are expected in the third quarter of 2025.
首批数据预计在2025年第三季度公布。
SAN DIEGO, July 22, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has completed enrollment in its global pivotal Phase 3 EFZO-FIT study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease with limited treatment options. The study enrolled 268 patients at 85 centers in 9 countries, exceeding target enrollment. Topline data from the study are expected in the third quarter of 2025.
2024年7月22日，加州圣迭戈市（全球新闻线）----aTyr Pharma, Inc(NASDAQ:ATYR)，一家从tRNA合成酶平台中发现和研发首创性药物的临床阶段的生物技术公司，今天宣布全球性开展的肺结核病(EFZO-FIt) III期临床试验（招募病例为268例）完成患者招募任务。肺结核病是一种主要的间质性肺疾病，治疗选择有限。研究于9个国家的85个中心进行，招募人数达268人，超过目标招募人数。首批数据预计在2025年第三季度公布。
